Doral, FL, January 09, 2018 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or, the “Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device R&D, is pleased to announce the company has signed a deal with Laboratories BNK Canada, Inc. (http://www.labobnk.com/), for clinical studies related to the MSN-2 Medical Device. BNK is a private laboratory, which will conduct the clinical studies required to add more tests to the company’s MSN-2 medical device-related services.
ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea. In the near future, ETST will add testing for trichomoniasis, and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. Both are highly infectious sexually transmitted infections (STI). These additions will help the company create sales opportunities in new markets.
BNK brings a team of professional scientists from the pharmaceutical, clinical research, and even hospital settings. BNK will assist ETST in the design, development, and validation of testing methods that meet all regulatory requirements. In addition, BNK will assist with the determination and development of study-specific tests for ETST clinical projects and bring expertise in clinical research project management to ensure that all trials run smoothly. This expertise will help the company maintain efficiency and reduce R&D costs.
“We are on the cusp of making tremendous progress in our clinical trial efforts,” said Dr. Michel Aubé, CEO and CSO of ETST. He continued, “Our partnership with BNK will allow us to leverage the expertise of R&D veterans of many years, which will help us move more quickly, develop more products, cut costs, and ultimately, treat more patients.”
Chlamydia and other sexually transmitted infections (STIs) often have permanent consequences for patients, and damage society at large. The World Health Organization now recommends that all pregnant women be tested for chlamydia, which has created a very large testing market. This partnership with BNK is expected to help ETST increase its total attainable market in this space, and allow the company to commercialize its new testing services more quickly.
“We are extremely happy to be working with Earth Science Tech on their MSN-2 project,” said Dr Gilles Brisson, President and Scientific Director at BNK . “This project has the potential to completely change the way we look at sampling for STI infections and is certainly a positive development in Women’s Health around the world. This collaboration will be the fundamental driver for the success of this project”.
It is essential that the spread of Sexually Transmitted Infections (STI) be halted. Michel Aubé PhD, Chief Science Officer states, “STI can have severe consequences. It is very important to prevent spreading. For example we can cure the Chlamydia infections but any permanent damage done by the long term infection will not be repaired.” Currently, two women are infected with Chlamydia for each infected man, and women generally have more complications. They may develop pelvic inflammatory disease, which leads to sterility, as well as chronic pain that persists even after the infection is cured. A newborn infected with Chlamydia by the mother may develop pneumonia and/or conjunctivitis that can lead to permanent blindness. For this reason, the World Health Organization recommends that all pregnant women be tested for Chlamydia. For these reasons, the market for Chlamydia testing alone is huge. ETST now has the laboratory partner needed to support the company’s R&D and the commercialization of its MSN-2 medical device, which has been specifically developed to support women’s health and the related molecular diagnostics that women desperately need access to.
About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.Earthsciencepharmaceutical.com
About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.Cannabisthera.com
About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.
To learn more please visit: www.kannabidioidinc.com
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Dave Demarest (305) 546-7640
Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305) 615-2118